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Human AlkB homolog 3 (ALKBH3), a homolog of the Escherichia coli protein AlkB, demethylates 1-me-
thyladenine and 3-methylcytosine (3-meC) in single-stranded DNA and RNA by oxidative demethylation.
Immunohistochemical analyses on clinical cancer specimens and knockdown experiments using RNA
interference in vitro and in vivo indicate that ALKBH3 is a promising molecular target for the treatment of
prostate, pancreatic, and non-small cell lung cancer. Therefore, an inhibitor for ALKBH3 demethylase is
expected to be a ﬁrst-in-class molecular-targeted drug for cancer treatment. Here, we report the de-
velopment of a novel, quantitative real-time PCR-based assay for ALKBH3 demethylase activity against
3-meC by highly active recombinant ALKBH3 protein using a silkworm expression system. This assay
enables us to screen for inhibitors of ALKBH3 demethylase, which may result in the development of a
novel molecular-targeted drug for cancer therapy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
AlkB is an Escherichia coli enzyme that demethylates 1-me-
thyladenine (1-meA) and 3-methylcytosine (3-meC) in single-
stranded (ss)DNA and double-stranded (ds)DNA through its
2-oxoglutarate- (2OG) and Fe(II)-dependent oxygenase domain
[1]. In humans, there are nine AlkB homologs (ALKBH) with the
2OG and Fe(II)-dependent oxygenase domain, which include
ALKBH1 to ALKBH8 [2,3] and fat mass and obesity-associated
(FTO) [4], also known as ALKBH9. Of the ALKBH family proteins,
ALKBH3 preferentially demethylates 1-meA and 3-meC in ssDNA
and RNA in a 2OG and Fe(II)-dependent manner [5,6].
ALKBH3, originally cloned as prostate cancer antigen-1 (PCA-1),
is overexpressed in prostate cancer tissues compared with non-
cancerous tissues [7]. Higher expression of PCA-1 was im-
munohistochemically conﬁrmed in human prostate cancer tissues
but not in normal adjacent prostate tissues or benign prostaticB.V. This is an open access article u
ethyladenine; 3-meC, 3-me-
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ujikawa).hyperplasia. Prostate cancer is the second leading cause of cancer-
related deaths in Western countries. Hormone therapy is effective
for patients with prostate cancer; however, many patients develop
castrate resistant prostate cancer (CRPC) within a few years. At
present, effective therapies are limited for prostate cancers re-
sistant to hormone therapy. Higher expression of ALKBH3 in
prostate cancer specimens is correlated with the development of
CRPC. Higher expression of ALKBH3 is also observed in pancreatic
cancer [8], non-small cell lung cancer (NSCLC) [9], as well as renal
cancer [10] specimens. In patients with these intractable cancers
and high ALKBH3 expression also have a poorer prognosis.
In CRPC, pancreatic cancer, and NSCLC, the development of
effective molecular-targeted drugs is highly desired. The knock-
down of ALKBH3 by RNA interference induced apoptotic cell death
in vitro and suppressed tumor formation in in vivo xenograft
models [8,11,12]. These results strongly indicate that ALKBH3 is a
promising molecular target for cancer therapy. However, to de-
velop a molecular-targeted drug for ALKBH3, it is necessary to
establish an assay to measure enzymatic activity, which could be
used to screen for lowmolecular weight compound inhibitors. Few
assays to measure the demethylase activity of ALKBH3 have been
described [13–15]. These assays, although sensitive and fast, re-
quire special equipment or reagents such as capillary electro-
phoresis with laser-based ﬂuorescence detection or mass spec-
trometer and radiolabeled substrates. Therefore, they arender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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weight compounds. In the present study, we obtained highly ac-
tive recombinant ALKBH3 protein using a silkworm expression
system. The production of recombinant ALKBH3 from silkworms
enabled us to develop a real-time PCR-based quantitative assay of
its demethylation activity against 3-meC in ssDNA.2. Materials and methods
2.1. Expression and puriﬁcation of recombinant ALKBH3 from silkworms
A silkworm vector, pMONFT21, for expression of human
ALKBH3 (NM_139178.3) cDNA encoding the FLAG-His-tagged
ALKBH3 (FLAG-His-ALKBH3) recombinant protein was constructed
by Link Genomics (Tokyo, Japan). The expression vector was co-
transfected with ABv baculovirus DNA into BmN cells to obtain the
recombinant virus (Sysmex, Hyogo, Japan). The silkworm pupae
were infected with the recombinant virus on the ﬁrst day after
pupation. Six days after infection, ten silkworm pupae expressing
FLAG-His-ALKBH3 were homogenized at 10,000 rpm for 5 min in
lysis buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene
glycol tetraacetic acid (EGTA), 10% glycerol, 10 mM benzamidine,
1 mM phenylmethylsulfonyl ﬂuoride, and 1 mM dithiothreitol. The
homogenates were then solubilized by incubating with 1% Triton
X-100 at 4 °C for 1 h. The lysate was centrifuged at 4 °C for 1 h at
100,000g. The protein puriﬁcation was performed in two steps in
order to achieve higher purity. First, the supernatant was puriﬁed
by a 5-mL, 1.62.5-cm HisTrap HP afﬁnity column (GE Healthcare)
at 4 °C, using AKTA Prime Plus (GE Healthcare). The fractions
containing recombinant FLAG-His-ALKBH3 were eluted with a
linear gradient of 60–280 mM imidazole in 20 mM Tris-HCl (pH
8.0), 150 mM NaCl, 10% glycerol, and 0.1% Triton X-100. Subse-
quently, the eluate fractions containing recombinant ALKBH3 were
diluted ﬁve-fold with 20 mM Tris-HCl (pH 8.0), 10% glycerol, and
0.1% Triton X-100 (binding buffer), and applied to a 0.55.0-cm
Mono Q 5/50 GL anion ion exchange column (GE Healthcare) at
4 °C, using AKTA Prime Plus (GE Healthcare). After extensive
washing with binding buffer containing 50 mM NaCl, recombinant
FLAG-His-ALKBH3 was eluted with a linear gradient of 500 mM
NaCl in the binding buffer, followed by dialysis in 20 mM Tris-HCl
(pH 8.0), 50 mM NaCl, 50% glycerol, and 0.1% Triton X-100. Purity
was conﬁrmed on a 10% sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) gel (Bio-Rad) stained with
SimplyBlue SafeStain (Life Technologies).
2.2. Western blot analysis with anti-ALKBH3 antibody
Puriﬁed recombinant FLAG-His-ALKBH3 was resolved on a 10%
denaturing acrylamide gel (Bio-Rad) and transferred to a poly-
vinylidene diﬂuoride membrane (Millipore). The membrane was
blocked with 3% bovine serum albumin at room temperature for
1 h. The membrane was incubated with anti-ALKBH3 antibody
(1:5000 dilution, Millipore #09-882) overnight at 4 °C and then
incubated with horseradish peroxidase-conjugated anti-rabbit IgG
(Santa Cruz Biotechnology). Bound horseradish peroxidase con-
jugates were visualized using enhanced chemiluminescence re-
agent (GE Healthcare) under ImageQuant LAS 4000 (GE
Healthcare).
2.3. Quantitative assay of ALKBH3 3-meC demethylase activity by
real-time PCR
The reaction solution of the ALKBH3 demethylation assay
comprised puriﬁed recombinant FLAG-His-ALKBH3 fromsilkworms (4 ng), 2 mM ascorbic acid, 100 μM 2-oxoglutarate,
40 μM Fe(SO)4 7H2O, and 80 fmol oligo ssDNA containing 3-meC
(GGAAACAGCTATGACCATGATTACTAGACATTGCCATTCTCGATAGGA
TCCGGTCAAACCTAGACGAATTCCGGT-3-meC-GTGACTGGGAAAACC
CTGGCG, Gene Design) as a substrate in 50 mM Tris-HCl (pH 8.0).
The reaction mixture was incubated for 1 h at 37 °C, and then di-
luted 20-fold with distilled water for quantitative real-time PCR
(qRT-PCR) analysis. The non-methylated ssDNA was used as a
standard template. The qRT-PCR analysis was performed using a
CFX96 real-time PCR system (Bio-Rad) in a total reaction volume
of 20 mL containing 2 mL of the diluted reaction mixture, and 18 mL
of Bio-Rad iQ SYBR Green Supermix with 200 nmol of each primer
(sense: GGAAACAGCTATGACCATGATTAC, antisense: CGCCAGGGT
TTTCCCAGTCGTG). Thermal cycling conditions were as follows: an
initial incubation at 95 °C for 10 s to activate the polymerase fol-
lowed by 40 cycles of 95 °C for 5 s, 61 °C for 30 s and 72 °C for 15 s.
The level of the ampliﬁed products was calculated from a standard
curve as the demethylation activity of ALKBH3 and ALKBH2. Re-
combinant His-tagged ALKBH2 (His-ALKBH2) and His-tagged
ALKBH3 (His-ALKBH3) from E. coli were purchased from Abcam.
2.4. Digestion of ssDNA oligo containing 3-meC demethylated by
ALKBH3 to nucleosides for LC-MS/MS analysis
After incubation with or without silkworm recombinant
ALKBH3, the ssDNA oligo containing 3-meC was puriﬁed by
ethanol-precipitation. The precipitate was suspended in 45 mL of
H2O, after which 5 mL of 0.1 m ammonium acetate (pH 5.3) and
0.5 units of nuclease P1 (Wako) were added. After incubating for
2 h at 45 °C, 5.5 mL of 1 m ammonium bicarbonate and 0.002 units
of venom phosphodiesterase II (Wako) were added to the mixture,
followed by additional incubation for 2 h at 25 °C. Thereafter, the
mixture was incubated for 1 h at 37 °C with 0.5 units alkaline
phosphatase (NEW ENGLAND BioLabs). HCl (1.3 mL, 0.1 N), H2O
(50 mL) and chloroform (20 mL) were then added. The sample was
vortexed and the resulting suspension was centrifuged for 5 min at
5000g. The aqueous layer was collected and evaporated to dryness.
The nucleosides left behind were solubilized in Milli-Q water.
2.5. LC-MS/MS conﬁrmation of 3-meC demethylation by ALKBH3
LC-ESI-MS/MS analyses were performed on a Waters ACQUITY
UPLC system (Waters) coupled to a Quattro Premier XE triple
quadrupole mass spectrometer (Waters). For DNA samples, LC
separations were carried out at 50 °C with an ACQUITY UPLC BEH
C18 column, 1.7 mm, 2.1100 mm (Waters). Mobile-phase A was
5 mM ammonium formate and 0.2% (v/v) formic acid, and mobile-
phase B was acetonitrile. The analyte was eluted with mixed
mobile-phase A and B (98/2, v/v) at a ﬂow rate of 0.3 mL/min. The
data for one run was acquired for 4 min. The mass spectrometer
was operated using an electrospray ionization (ESI) source in the
positive mode. ESI-MS/MS was conducted in the negative ion
mode. The ionization parameters were capillary voltage, 3.0 kV;
extractor voltage, 2 V; source temperature, 120 °C; desolvation
temperature, 350 °C; desolvation gas ﬂow, 800 L/h; cone gas ﬂow,
50 L/h. Selected reaction monitoring (SRM) transitions (m/z of
precursor ion/m/z of product ion) and parameters (cone voltage
and collision energy) for the deoxynucleosides are listed in Sup-
plementary Table 1. Inter-channel delay and inter-scan delay were
set at 0.01 and 0.05 s, respectively. The dwell time for each SRM
was set at 50 ms.
Statistics. Differences between values were statistically ana-
lyzed using a Student’s t-test. A p-valueo0.05 was considered
statistically signiﬁcant.
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3.1. Production and puriﬁcation of recombinant ALKBH3 from silk-
worm pupae
To develop an in vitro assay of ALKBH3 demethylase activity, a
reliable supply of soluble and enzymatically active ALKBH3 protein
is required. In protein expression, E. coli strains are routinely used;
however, since recombinant ALKBH3 protein was mainly con-
tained in inclusion bodies as aggregates, we could not obtain a
sufﬁcient amount of soluble recombinant ALKBH3 protein. Wes-
tern blot analysis did not yield any band corresponding to the
human ALKBH3 protein, which indicated that the yield was either
extremely low or there was no yield at all (data not shown). The
baculovirus-silkworm larvae expression system has been used to
efﬁciently produce large amounts of recombinant proteins with
biological activity [16]. Therefore, we tested whether a silkworm
expression system would enable the production and puriﬁcation
of soluble recombinant ALKBH3 protein.
A silkworm expression vector containing FLAG-His-ALKBH3
cDNA was constructed and recombinant FLAG-His-ALKBH3 was
expressed in 10 silkworm pupae. We discovered that the suc-
cessful solubilization of recombinant FLAG-His-ALKBH3 can be
achieved by the addition of 1% Triton X-100 to the homogenate of
silkworm pupae (Fig. 1A). The supernatant containing soluble re-
combinant FLAG-His-ALKBH3 was obtained after ultracentrifuga-
tion of the homogenate. In order to achieve high purity, the re-
combinant FLAG-His-ALKBH3 was puriﬁed by a two-step afﬁnity
chromatography using a nickel afﬁnity column and an anion ex-
change column (Supplementary Table 2). Puriﬁed recombinant
FLAG-His-ALKBH3 was detected as a single, approximately 37-kDa
band, which is its estimated molecular weight on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. Im-
munoblot analysis with an anti-ALKBH3 antibody, anti-Histag
antibody and anti-FLAG tag antibody indicated that these bands
were the recombinant ALKBH3. (Fig. 1B, Supplementary Fig. 1A
and B). The yield of puriﬁed recombinant FLAG-His-ALKBH3 was
0.6 mg from 10 silkworm pupae.1 2 3 4 5
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Fig. 1. Puriﬁcation of recombinant FLAG-His-ALKBH3 protein from silkworm pu-
pae. (A) Silkworm pupae expressing FLAG-His-ALKBH3 were homogenized and
puriﬁed by two-step afﬁnity chromatography. Aliquots of the homogenate super-
natant and puriﬁed fractions were resolved on a 10% SDS-PAGE gel and stained
with Coomassie R-250. Lane 1, protein molecular weight markers; lane 2, input
lysate; lane 3, ﬂow-through fraction of nickel column; lane 4, eluant from the nickel
column; lane 5, eluant puriﬁed by ion-exchange column. (B) Immunoblot analysis of
puriﬁed recombinant FLAG-His-ALKBH3 protein (2 ng) using an anti-ALKBH3 antibody.3.2. Potent 3-meC demethylation activity of recombinant ALKBH3
from silkworms
The enzymatic activity of puriﬁed recombinant FLAG-His-
ALKBH3 was studied. ALKBH3 has potent demethylation activity
against 3-meC in ssDNA in the presence of 2-OG and Fe(II).
Therefore, as a substrate to study ALKBH3's enzymatic activity, we
synthesized a unique 97 bp ssDNA oligonucleotide containing one
3-meC residue (referred to as 3-meC ssDNA). The sequence of the
oligonucleotide was derived from a sequence found in a conven-
tional cloning vector and its length was determined by taking into
consideration the detection sensitivity of the following qRT-PCR
analysis. 3-meC ssDNAwas incubated with recombinant FLAG-His-
ALKBH3 in the presence of 2-OG and Fe(II) at 37 °C for 1 h. After
1 h incubation, the 3-meC ssDNA in the reaction mixture was
precipitated by ethanol and then resuspended in distilled water.
Then the 3-meC ssDNA was incubated with nuclease P1 and ve-
nom phosphodiesterase II to digest phosphodiester bonds of the
nucleotides, followed by incubation with alkaline phosphatase.
The obtained nucleoside solution was treated with chloroform to
remove proteins and then dried. The levels of nucleic acid bases
and 3-meC in the samples were analyzed with LC-MS/MS. A peak
representing 3-meC, which was detected in the control sample
(Fig. 2A), could not be detected in the sample incubated withALKBH3
+ 2OG, Fe(II)
Retention time (min)
R
el
at
iv
e 
in
te
ns
ity
(%
) 1.24
1.99
3.17
0
100
1.24
1.99
1.44
3.17
1.00 2.00 3.000.50 1.50 2.50
0
100
ALKBH3
- 2OG, Fe(II) 3-meC
C
Fig. 2. Recombinant ALKBH3 from silkworm demethylates 3-meC in ssDNA oligo-
nucleotides in a 2-OG and Fe(II)-dependent manner. Single-stranded DNA oligo-
nucleotides containing 3-meC was incubated without (A) or with FLAG-His-
ALKBH3 in the presence (B) or absence (C) of 2-OG/Fe(II). The ssDNA oligonu-
cleotides were digested to nucleosides and analyzed by LC-MS/MS. Retention times
are shown above each peak. A peak representing 3-meC was detected at a retention
time of approximately 1.4 min.
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Fig. 3. qRT-PCR analysis of recombinant ALKBH3 demethylation activity against
3-meC ssDNA. Demethylation activity of recombinant ALKBH3 was analyzed by
qRT-PCR. (A) The amount of demethylated product was estimated from a standard
curve using ssDNA oligonucleotides without 3-meC. (B) The demethylation of
3-meC ssDNA by FLAG-His-ALKBH3 was measured in the presence or absence of
2-OG and/or Fe (II). Heat denatured: recombinant FLAG-His-ALKBH3 was heat-in-
activated at 95 °C for 10 min. (C) The level of demethylated 3-meC ssDNA converted
by recombinant ALKBH3 was determined in a time-dependent manner. All data
shown are representative of at least three independent experiments. *po0.05.
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However, recombinant ALKBH3 did not exhibit 3-meC demethy-
lase activity in the absence of 2-OG and Fe(II) (Fig. 2C). The peak
intensities of the bases (C, G, A, and T) were comparable in the
samples incubated with or without recombinant ALKBH3 in the
presence or absence of 2-OG and Fe(II). These results indicate that
recombinant FLAG-His-ALKBH3 was successfully puriﬁed from
silkworms and retained its demethylase activity.
3.3. The development of a quantitative assay to measure ALKBH3
demethylase activity by qRT-PCR
Previous evidence indicated that ALKBH3 might be a promising
molecular target for CRPC, pancreatic cancer and NSCLC. To de-
velop a molecular-targeted drug that targets ALKBH3, the estab-
lishment of an inhibitor screen for ALKBH3 demethylase is ne-
cessary. Since the N3-position of cytosine is involved in Watson-
Crick base paring in dsDNA through hydrogen bonds, we assumed
that a methylated residue at that position would disturb the an-
nealing of a PCR primer. Moreover, qRT-PCR might provide a more
quantitative and higher-throughput assay for screening small
molecular weight compounds that inhibit ALKBH3 demethylase
activity. Thus, for our ALKBH3 demethylation assay, we decided to
perform qRT-PCR using a reverse primer with a mismatch at the
second and third bases before the 3′-end (Supplementary Table 3)
and found that the qRT-PCR detected the DNA demethylation in a
methylated DNA content-dependent manner (Supplementary
Fig. 2). First, we examined the concentration-dependence of re-
combinant ALKBH3 in the demethylation reaction. In a 10 μL re-
action, the substrate, an oligo ssDNA containing one 3-meC, was
incubated with various amounts of recombinant ALKBH3 in the
presence of 2-OG and Fe(II) for 1 h. The reaction was then diluted
20-fold with distilled water. This dilution step was found to be
suitable for the following reasons: further recombinant ALKBH3
demethylase activity was effectively quenched, and dilution did
not interfere with the following qRT-PCR reaction in a 96-well
plate. The diluted samples were then directly added to a qRT-PCR
reaction solution. qRT-PCR analysis indicated that demethylation
activity against 3-meC ssDNA was linear in a range of 0–6 ng of
recombinant ALKBH3 (Fig. 3A). Therefore, we decided to use 4 ng
of recombinant ALKBH3, which had approximately 90% the max-
imum demethylation activity observed in our assay.
It is accepted that 2-OG and Fe(II) are essential for ALKBH3
demethylation activity. Indeed, the dependence of ALKBH3 de-
methylase activity on 2-OG and Fe(II) was quantitatively con-
ﬁrmed in our assay. As shown in Fig. 3B, the demethylase activity
of recombinant ALKBH3 against 3-meC in ssDNA was observed
only when both 2-OG and Fe(II) were present. On the other hand,
heat-denatured recombinant ALKBH3 exhibited no enzymatic ac-
tivity even in the presence of 2-OG or Fe(II).
Next, the dependence of ALKBH3 demethylase activity on the
time of incubation was determined in our qRT-PCR assay. Re-
combinant ALKBH3 was incubated with 3-meC ssDNA in the pre-
sence of 2-OG and Fe(II) for 1–120 min. As shown in Fig. 3C and
Supplementary Fig. 3, 3-meC demethylation by recombinant
ALKBH3 was rapid, and approximately 50% of 3-meC in ssDNA was
demethylated within 10 min. To achieve the complete demethy-
lation of 3-meC in ssDNA by recombinant ALKBH3, an incubation
time of 1 h was required.
Finally, we compared the 3-meC demethylation activity of re-
combinant FLAG-His-ALKBH3 from silkworms with commercially
available recombinant His-ALKBH2 and His-ALKBH3 from E. coli.
ALKBH3 prefers as a substrate 3-meC in ssDNA to that in dsDNA.
On the other hand, ALKBH2 preferentially demethylates 3-meC in
dsDNA. Our qRT-PCR assay showed that recombinant FLAG-His-
ALKBH3 from silkworms had demethylase activity against 3-meCssDNA more than 400-fold greater than recombinant ALKBH3
from E. coli (Fig. 4). As expected, ALKBH2 showed weak de-
methylation activity against 3-meC in ssDNA. These results in-
dicate that our qRT-PCR-based ALKBH3 demethylase assay can be
useful for screening potential ALKBH3 inhibitors.
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Fig. 4. Comparison of 3-meC ssDNA demethylase activity of ALKBH2 and ALKBH3 from E. coli and FLAG-His-ALKBH3 from silkworms. Concentration-dependent demethylase
activity of ALKBH2 and ALKBH3 from E. coli were determined in our qRT-PCR assay and compared to the activity of 4 ng of recombinant FLAG-His-ALKBH3 from silkworms
(open circle). Data shown are representative of three independent experiments.
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We [7] and Liu et al. [17] have reported that ALKBH3, which was
originally cloned as PCA-1, is highly expressed in prostate cancer
tissues but not in normal prostate tissues or benign prostatic hy-
perplasia. The knockdown of ALKBH3 induces apoptosis of prostate
cancer cells in vitro and suppresses tumor formation in an in vivo
xenograft model [7,12]. ALKBH3 is unique in its enzymatic activity
by being able to demethylate 1-meA and 3-meC in ssDNA/RNA in a
2-OG/Fe(II)-dependent manner [5,6]. Dango et al. have demon-
strated that ALKBH3 enzymatic activity is critical for the growth of
prostate cancer cells through the following mechanism [18].
ALKBH3 is associated with a helicase, activating signal cointegrator
complex 3 (ASCC3). 3-meC produced by endogenous cellular me-
tabolism or exogenous alkylating agents blocks Watson-Crick base
pairing, leading to errors during DNA synthesis. ASCC3 unwinds
dsDNA into ssDNA to expose 3-meC, making it accessible for de-
methylation by ALKBH3. On the other hand, RNA demethylation by
ALKBH3 seems to increase the efﬁciency of protein synthesis in
cancer cells (unpublished data). Recently, the high expression of
ALKBH3 was also found in pancreatic cancers [8] and NSCLCs [9].
Therefore, ALKBH3 is a promising molecular target for the treat-
ment of these cancers, and an inhibitor of its demethylase activity
may represent a ﬁrst-in-class cancer therapeutic agent. Here, we
have established a useful demethylation assay for ALKBH3.
To develop a new molecular-targeted drug for cancer, a speciﬁc
and sensitive assay to measure a target molecule’s activity must be
established before screening for potential inhibitors from a library
of low molecular weight compounds. A few assays to measure the
demethylase activity of AlkB have been described [13–15]. These
assays are sensitive and fast but require special equipment or re-
agents, such as radiolabeled substrates, capillary electrophoresis
with laser-based ﬂuorescence detection or mass spectrometry.
Therefore, they are unsuitable for a high throughput screen of low
molecular weight compounds. We established a qRT-PCR assay to
measure ALKBH3 demethylase activity, which is based on the poor
annealing of a primer that carries two mismatch bases to an ssDNA
substrate containing 3-meC. A notable advantage of our assay is
that many compounds (up to 384 samples depending on the qRT-
PCR machine used) can be tested rapidly (within 2 h) and quan-
titatively in parallel.
Recently, by using our assay, Nakao et al. have reported that 1-
(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-
5-ol has potent inhibitory activity against ALKBH3 demethylation
[19]. Moreover, this compound inhibits prostate cancer cell growthin vitro and showed anti-tumor activity in an in vivo prostate
cancer xenograft model. Optimization of the speciﬁcity and po-
tency of this compound is the subject of future studies. However,
these results demonstrate that our assay is useful in screening a
large-scale chemical library.
Taken together, we have developed a quantitative, sensitive and
high-throughput assay to screen for inhibitors of ALKBH3 de-
methylase. Since ALKBH3 represents a potential molecular target
for CRPC, pancreatic cancer, NSCLC, and renal cancer [10], a high
throughput screen using our assay might contribute to the de-
velopment of a novel molecular-targeted agent.Acknowledgements
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